The T-Cell Immune Response Against Kaposi's Sarcoma-Associated Herpesvirus

Overview

Journal Adv Virol

Publisher Wiley

Specialty Microbiology

Date 2012 Feb 15

PMID 22331985

Citations 23

Authors

Rebecca C Robey

Salvinia Mletzko

Frances M Gotch

Affiliations

Soon will be listed here.

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the aetiological agent of Kaposi's sarcoma (KS), the most frequently arising malignancy in individuals with untreated HIV/AIDS. There are several lines of evidence to indicate that Kaposi's sarcoma oncogenesis is associated with loss of T-cell-mediated control of KSHV-infected cells. KSHV can establish life-long asymptomatic infection in immune-competent individuals. However, when T-cell immune control declines, for example, through AIDS or treatment with immunosuppressive drugs, both the prevalence of KSHV infection and the incidence of KS in KSHV carriers dramatically increase. Moreover, a dramatic and spontaneous improvement in KS is frequently seen when immunity is restored, for example, through antiretroviral therapy or the cessation of iatrogenic drugs. In this paper we describe the current state of knowledge on the T-cell immune responses against KSHV.

Citing Articles

Association between KSHV-Specific Humoral and T Cell Responses with Recurrence of HIV-Associated Kaposi Sarcoma.

Mukasine M, Mulundu G, Kawimbe M, Mutale K, Mumba C, Lidenge S Trop Med Infect Dis. 2024; 9(6).

PMID: 38922046 PMC: 11209129. DOI: 10.3390/tropicalmed9060134.

Editorial: Infectious disease agents and cancer.

Igea A, Martin O, Cooks T, Pateras I Front Cell Dev Biol. 2024; 12:1388423.

PMID: 38533087 PMC: 10964319. DOI: 10.3389/fcell.2024.1388423.

The impact of HLA polymorphism on herpesvirus infection and disease.

Palmer W, Norman P Immunogenetics. 2023; 75(3):231-247.

PMID: 36595060 PMC: 10205880. DOI: 10.1007/s00251-022-01288-z.

Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus.

Boni M, Rieble L, Munz C Viruses. 2022; 14(12).

PMID: 36560713 PMC: 9782805. DOI: 10.3390/v14122709.

Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus.

Nalwoga A, Whitby D Curr Opin Immunol. 2022; 77:102230.

PMID: 35810680 PMC: 9578218. DOI: 10.1016/j.coi.2022.102230.

References

Lennette E, Blackbourn D, Levy J . Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet. 1996; 348(9031):858-61. DOI: 10.1016/S0140-6736(96)03240-0. View

Duprez R, Lacoste V, Briere J, Couppie P, Frances C, Sainte-Marie D . Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst. 2007; 99(14):1086-94. DOI: 10.1093/jnci/djm045. View

Hladik W, Dollard S, Downing R, Kataaha P, Pellett P, Karon J . Kaposi's sarcoma in Uganda: risk factors for human herpesvirus 8 infection among blood donors. J Acquir Immune Defic Syndr. 2003; 33(2):206-10. DOI: 10.1097/00126334-200306010-00015. View

Landais E, Saulquin X, Bonneville M, Houssaint E . Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen. J Immunol. 2005; 175(12):7939-46. DOI: 10.4049/jimmunol.175.12.7939. View

Lambert M, Gannage M, Karras A, Abel M, Legendre C, Kerob D . Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood. 2006; 108(12):3871-80. DOI: 10.1182/blood-2006-03-014225. View

Osman M, Kubo T, Gill J, Neipel F, Becker M, Smith G . Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol. 1999; 73(7):6136-40. PMC: 112681. DOI: 10.1128/JVI.73.7.6136-6140.1999. View

De Maria A, Ferrazin A, Ferrini S, Ciccone E, Terragna A, Moretta L . Selective increase of a subset of T cell receptor gamma delta T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J Infect Dis. 1992; 165(5):917-9. DOI: 10.1093/infdis/165.5.917. View

Gredmark-Russ S, Cheung E, Isaacson M, Ploegh H, Grotenbreg G . The CD8 T-cell response against murine gammaherpesvirus 68 is directed toward a broad repertoire of epitopes from both early and late antigens. J Virol. 2008; 82(24):12205-12. PMC: 2593319. DOI: 10.1128/JVI.01463-08. View

Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I . Primary human herpesvirus 8 infection in immunocompetent children. JAMA. 2002; 287(10):1295-300. DOI: 10.1001/jama.287.10.1295. View

10.

Barozzi P, Riva G, Vallerini D, Bosco R, Quadrelli C, Zanetti E . Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients. Transplantation. 2009; 88(4):597-8. DOI: 10.1097/TP.0b013e3181b15d56. View

11.

Gill P, Tsai Y, Rao A, Spruck 3rd C, Zheng T, Harrington Jr W . Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A. 1998; 95(14):8257-61. PMC: 20963. DOI: 10.1073/pnas.95.14.8257. View

12.

Bihl F, Narayan M, Chisholm 3rd J, Henry L, Suscovich T, Brown E . Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. J Virol. 2007; 81(9):4904-8. PMC: 1900166. DOI: 10.1128/JVI.02509-06. View

13.

Cesarman E, Mesri E, Gershengorn M . Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?. J Exp Med. 2000; 191(3):417-22. PMC: 2195817. DOI: 10.1084/jem.191.3.417. View

14.

Stebbing J, Bourboulia D, Johnson M, Henderson S, Williams I, Wilder N . Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol. 2003; 77(7):4306-14. PMC: 150628. DOI: 10.1128/jvi.77.7.4306-4314.2003. View

15.

Taylor G, Long H, Haigh T, Larsen M, Brooks J, Rickinson A . A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol. 2006; 177(6):3746-56. DOI: 10.4049/jimmunol.177.6.3746. View

16.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View

17.

Parkin D, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H . Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol. 2008; 9(7):683-92. DOI: 10.1016/S1470-2045(08)70175-X. View

18.

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

19.

Ribechini E, Fortini C, Marastoni M, Traniello S, Spisani S, Monini P . Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8. J Immunol. 2006; 176(2):923-30. DOI: 10.4049/jimmunol.176.2.923. View

20.

Pellett P, Wright D, Engels E, Ablashi D, Dollard S, Forghani B . Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003; 43(9):1260-8. DOI: 10.1046/j.1537-2995.2003.00490.x. View